The production site of the Russian biopharmaceutical company Promomed — the Biokhimik plant in Saransk — has successfully passed an audit by the Ministry of Health of Uzbekistan, confirming compliance with international GMP standards, TASS reports, citing the pharmaceutical manufacturer’s press service.
“The Biokhimik plant has successfully passed an audit by the Ministry of Health of the Republic of Uzbekistan and confirmed its compliance with international GMP standards. The certificate opens the opportunity for supplying Promomed’s medicines to one of the most dynamically developing pharmaceutical markets in Eurasia,” the statement reads.
The company plans to register a “wide portfolio of drugs” in Uzbekistan, including endocrinological, oncological, antibacterial, and cardiovascular medications, totaling more than 20 items in various forms and dosages.
Promomed’s production portfolio includes over 360 drugs. Earlier this year, it became known that the pharmaceutical manufacturer is entering the veterinary medicines market.
